| Patient | Jack London |
|---|---|
| Date of birth | 1987-01-12 |
| Identifiers | MRN HR-ET010-SYN; SSN (made up) 000-10-4482 |
| Document date | 2026-10-13 |
| Author | Eleanor Whitcombe-Ibe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Ten-week review. [S]
Mr. London has had no alcohol for six weeks, since the evening of the ankle sprain. He takes naltrexone and losartan 100 mg every morning; he has had no dizziness. His home readings average 124/78. He eats two meals a day now, and has not missed a meal or been unwell for weeks. The ankle has healed and he is riding again. He writes every morning and has finished a long story. He has kept up weekly counseling. [S]
| Element | Detail |
|---|---|
| Alcohol | None for six weeks; PEth 8 ng/mL |
| Potassium and creatinine | 5.0 mmol/L; 1.95 mg/dL (eGFR 44) four weeks after losartan 100 mg |
| Home readings | Average 124/78 mmHg |
| Ankle | Healed |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; eating regularly |
| Cardiovascular | Negative | No dizziness or ankle swelling |
| Genitourinary | Negative | No urinary or genital symptoms |
| Psychiatric | Negative | Mood good; cravings rare; no thoughts of self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intake | One tablet by mouth twice a day, self-directed | Oral route | 2024-08-01 to 2026-08-04 | stopped | S |
| Losartan 50 mg oral tablet once daily | One tablet by mouth every morning | Oral route | 2026-08-04 to 2026-09-15 | completed | S |
| Losartan 100 mg oral tablet once daily | One tablet by mouth every morning | Oral route | 2026-09-15 | active | S |
| Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone check | Up to one capsule four times a day on day 1, tapering to one a day by day 4; stop after day 5; no alcohol or driving | Oral route | 2026-08-04 to 2026-08-08 | completed | S |
| Thiamine 100 mg oral tablet once daily | One tablet by mouth daily | Oral route | 2026-08-04 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxen | One to two tablets by mouth every six hours as needed; no more than four tablets a day | Oral route | 2026-08-04 | active | S |
| Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicines | One tablet by mouth every morning | Oral route | 2026-08-18 | active | S |
| Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily | One tablet by mouth daily | Oral route | 2026-09-15 | active | S |
| Dapagliflozin 10 mg oral tablet once daily, held on any day he cannot eat or drink normally, and before surgery | One tablet by mouth every morning; sick-day rules in writing | Oral route | 2026-10-13 | active | S |
| Diclofenac 1% gel, 4 g rubbed into the outer right ankle four times a day for up to seven days, in place of any oral anti-inflammatory medicine | Apply 4 g to the ankle four times a day for up to seven days | Topical route | 2026-09-01 to 2026-09-08 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-13 | Body height | 173 | cm | S |
| 2026-10-13 | Body weight | 81.4 | kg | S |
| 2026-10-13 | Body mass index (BMI) [Ratio] | 27.2 | kg/m2 | S |
| 2026-10-13 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-13 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-10-13 | Heart rate | 72 | /min | S |
| 2026-10-13 | Respiratory rate | 14 | /min | S |
| 2026-10-13 | Body temperature | 36.6 | Cel | S |
| 2026-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-13 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-13 | Potassium [Moles/volume] in Serum or Plasma | 5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-13 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-10-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.95 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-10-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 44 | mL/min/{1.73_m2} | 45 to 59 is G3a; 30 to 44 is G3b | Low | S |
| 2026-10-13 | Phosphatidylethanol [Mass/volume] in Blood | 8 | ng/mL | Below 20 ng/mL abstinence or light drinking; above 200 heavy drinking | Normal | S |
Vital signs recorded on 2026-10-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 126/80, pulse 72; weight 81.4 kg |
| Cardiovascular | Regular rhythm; no edema |
| Musculoskeletal | Right ankle normal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultation | resolved | confirmed | R94.4 | S — Synthetic presenting problem anchored to the documented kidney damage found in 1913; superseded when the consultation staged chronic kidney disease. |
| Chronic kidney disease, stage G3b A2 (eGFR 42 to 43, urine albumin 240 mg/g), most likely from hypertension with a contribution from two years of daily naproxen; kidneys of normal size, without stones or obstruction; urine sediment bland; synthetic modern diagnosis linked to his documented kidney disease | active | confirmed | N18.32 | S — Synthetic modern diagnosis made at the consultation, anchored to his documented kidney damage and death from uraemia; the cause in the modern episode is synthetic and is not a claim about his real kidneys. |
| Hypertensive chronic kidney disease, untreated until intake | active | confirmed | I12.9 | S — Synthetic modern diagnosis made at the consultation. |
| Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mL | active | confirmed | F10.20 | S — Synthetic modern diagnosis anchored to his own published account of heavy drinking; the criteria, scores and amounts are synthetic and are not a claim about his real drinking. |
| Alcohol-associated fatty liver without advanced fibrosis (liver stiffness 7.2 kPa; steatosis on ultrasound); FIB-4 2.28 at intake | active | confirmed | K70.0 | S — Synthetic finding of the ultrasound and elastography at the consultation; not a claim about his real liver. |
| Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its place | resolved | confirmed | Z79.1 | S — Synthetic medication history; the joint pain is anchored to the documented rheumatism of 1914, which is not given a diagnosis. |
| Cigarette smoking, about ten a day; not ready to stop while he stops drinking | active | confirmed | F17.210 | S — Synthetic tobacco use; a physician-author's suggestion of heavy tobacco use is recorded only as a retrospective claim. |
| Right ankle sprain (lateral ligaments, moderate), from stepping into a burrow while walking the pasture; Ottawa ankle rules negative; healed in about four weeks | resolved | confirmed | S93.401A | S — Synthetic acute injury; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated device, average of readings) | Every visit | Completed today | 126/80 mmHg; home average 124/78 |
| Laboratory | Potassium and creatinine after starting or changing losartan or an SGLT2 inhibitor | Two to four weeks after each start or change | Completed today | Four weeks after losartan 100 mg: potassium 5.0 mmol/L, creatinine 1.95 mg/dL; dapagliflozin started today, recheck in two weeks |
| Laboratory | Creatinine with eGFR and urine albumin-to-creatinine ratio | G3b A2: twice a year, and at each medicine check | Completed today | eGFR 44; urine albumin due at twelve weeks |
| Laboratory | Electrolytes and bicarbonate | With each kidney test | Completed today | Sodium 139; bicarbonate 23 mmol/L |
| Medication safety | SGLT2 inhibitor safety: sick-day rules, ketoacidosis, genital infection, volume | At the start and every visit | Completed today | Started today after six weeks of abstinence and regular meals; sick-day rules in writing; genital hygiene explained |
| Medication safety | Medication reconciliation: no NSAIDs, kidney dosing, contrast safety | Every visit | Completed today | No NSAIDs; dapagliflozin added |
| Self-management | Lifestyle: sodium below 2 g a day, activity, diet, weight | Every visit | Completed today | Riding and swimming; less salt |
| Survey | Drinking since the last visit (self-report) | Every visit | Completed today | None for six weeks |
| Laboratory | PEth | At baseline and every four to six weeks in early recovery | Completed today | 8 ng/mL: abstinence |
| Laboratory | Liver tests (AST, ALT, GGT) on naltrexone | At baseline, at four to six weeks, then every few months | Up to date | Normal-range at six weeks; next at twelve weeks |
| Medication safety | Naltrexone safety: opioid use, nausea, wallet card | Every visit | Completed today | No nausea; no opioid |
| Referral | Addiction-focused counseling and mutual help | Weekly in early recovery | Completed today | Weekly sessions kept |
| Survey | Suicide-risk review, firearms storage, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; firearms locked; 988 card carried |
| Self-management | Tobacco use and readiness to stop | Every visit | Completed today | About ten a day; thinking about a quit date |
Goal progress:
Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Twelve-week review in two weeks with potassium, creatinine, urine albumin, liver tests, PEth, AUDIT, PHQ-9 and GAD-7. Counseling weekly. The clinic or 988 at any hour. Next scheduled visit 2026-10-27: twelve-week review: kidney function after the SGLT2 inhibitor, urine albumin, liver tests, AUDIT, mood, safety and the plan ahead. [S]